Ablynx has announced additional results from the Phase III Hercules study with caplacizumab
Ablynx NV [Euronext Brussels and Nasdaq: ABLX] today announced additional results from the Phase III HERCULES study with caplacizumab, the…
Results of the Randomized, Double-Blind, Placebo-Controlled, Phase III HERCULES study of Caplacizumab in Patients with Acquired Thrombotic Thrombocytopenic Purpura to be presented at he 59th Annual Meeting of the American Society of Hematology
Ablynx NV [Euronext Brussels and Nasdaq: ABLX] has announced that results from its Phase III HERCULES study of caplacizumab have been selected…